Abstract
Circulating tumor DNA (ctDNA) is a noninvasive strategy to disease assessment of minimal residual disease and treatment response for advanced cancer. ctDNA is emerging as a tool for use in clinical practice and informing novel clinical trial designs in melanoma.
| Original language | English |
|---|---|
| Pages (from-to) | 1646-1648 |
| Number of pages | 3 |
| Journal | Cancer |
| Volume | 129 |
| Issue number | 11 |
| Early online date | 4 Mar 2023 |
| DOIs | |
| Publication status | Published - 1 Jun 2023 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Biomarkers, Tumor/genetics
- Circulating Tumor DNA/genetics
- Humans
- Immunotherapy
- Neoplasms/genetics
Fingerprint
Dive into the research topics of 'Potential of circulating tumor DNA to refine immunotherapy.'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver